Welcome to our dedicated page for Creative Med Technology Hldgs SEC filings (Ticker: CELZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Creative Medical Technology Holdings, Inc.'s SEC filings document governance, capital-structure actions and material events for a clinical-stage regenerative medicine company. Proxy statements cover annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification and stockholder voting tied to Nasdaq share-issuance rules.
Current reports describe warrant exercise inducement agreements, private-placement warrant issuance, registered share issuance under a Form S-3, working-capital use of proceeds and board compensation actions. The filings frame the company's disclosure record around common stock, warrants, shareholder approvals, executive compensation and public-company governance.
Creative Medical Technology Holdings entered into warrant exercise inducement letters, prompting holders of warrants for 2,790,340 shares to exercise at $1.60 per share, generating approximately $4.5 million in gross proceeds. In return, the company reduced the original $2.86 exercise price and issued new Inducement Warrants for 5,580,680 shares at $1.60 per share.
The Inducement Warrants were issued in a private placement, will become exercisable only after required stockholder approval and then remain exercisable for five years. The company plans to file a resale registration statement on Form S-3 within thirty days. Roth Capital Partners will receive an 8% advisory fee on gross proceeds plus $50,000 for legal expenses. Separately, the compensation committee approved a $100,000 bonus for CEO Timothy Warbington.
Creative Medical Technology Holdings, Inc. is asking stockholders at a Special Meeting to approve two proposals: (1) amend the Articles of Incorporation to increase authorized Common Stock from 25,000,000 shares to 100,000,000 shares; and (2) approve the exercise in full of 5,580,680 Investor Warrants at $1.60 per share. The record date for voting was June 30, 2026, when 4,741,838 shares were outstanding. The Board unanimously recommends a FOR vote on both proposals.
Creative Medical Technology Holdings, Inc. is registering 3,045,685 shares of common stock, 6,091,371 Public Warrants, 3,045,685 pre-funded warrants, and up to 9,137,056 shares of common stock underlying those warrants in a best efforts public offering. The assumed combined public offering price is $1.97 per share and accompanying Public Warrants, implying estimated net proceeds of about $5.34 million. Common shares outstanding would rise from 3,696,668 to 6,742,353 if only shares (and no pre-funded warrants) are sold, before any warrant exercises, creating immediate dilution of $0.37 per share for new investors. Pro forma cash would increase from $5.72 million to $11.06 million as of March 31 2026. The company plans to use proceeds mainly to advance its AlloStemSpine® back pain trial (CELZ‑201‑DDT ADAPT), Type 1 diabetes study (CELZ‑201 CREATE‑1), its IPScelz™ iPSC program with Greenstone, other pipeline work, and general corporate purposes.
Creative Medical Technology Holdings is conducting a best efforts public offering of up to 3,045,685 shares of common stock, warrants to purchase up to 6,091,371 shares, pre-funded warrants to purchase up to 3,045,685 shares, and up to 9,137,056 shares underlying those warrants.
The assumed combined offering price is $1.97 per share and accompanying warrants, implying estimated net proceeds of about $5.34 million, which the company plans to use primarily to advance multiple CELZ-201 and CELZ-001 clinical programs, its IPScelz™ platform, and for working capital. Shares outstanding would rise from 3,696,668 to 6,742,353 if the full common stock amount is sold.
Creative Medical Technology Holdings reported a net loss of $1.4 million for the quarter ended March 31, 2026, slightly improved from $1.6 million a year earlier, as it reduced research and development spending.
Revenue was negligible, with no sales this quarter versus $3,000 in the prior-year period. Cash and cash equivalents totaled $5.7 million, down from $7.2 million at year-end, after using $1.3 million in operating cash and $175,000 for investments, including a related-party SPAC initiative and convertible notes.
The company continues to focus on its regenerative medicine pipeline, highlighting progress in AlloStemSpine® chronic lower back pain trials, CELZ-201 programs for Type 1 diabetes, and collaborations using induced pluripotent stem cells and artificial intelligence.
Creative Medical Technology Holdings, Inc. files an amended annual report outlining its 2025 governance, executive pay, related-party transactions and auditor fees. The company reports a non‑affiliate market value of common stock of $4,633,334 as of June 30, 2025 and 3,696,668 shares outstanding as of March 20, 2026.
The CEO earned total 2025 compensation of $732,720 and the CFO $560,000, with employment agreements providing salary, target bonuses and equity grants plus two years of salary and bonuses upon certain terminations. Three of five directors are independent and all three independents serve on the audit committee.
The filing details related-party arrangements, including a prior $5,000,000 purchase of research tools from an affiliate, a patent purchase agreement with contingent cash-or-stock milestone payments and royalties, the Bionance investment initiative with up to $600,000 of member commitments, and a $125,000 investment in a SPAC sponsor alongside the CEO. Audit and audit-related fees to Haynie & Company totaled $90,500 for 2025.
Creative Medical Technology Holdings filed its annual report detailing 2025 operations, clinical progress and risks. The company is a commercial-stage biotech focused on regenerative therapies for Type 1 and Type 2 diabetes, chronic lower back pain, infertility and other immune‑mediated conditions.
Key 2025 milestones include continued Phase I/II trials for Type 1 diabetes (CELZ-201 CREATE-1) and AlloStemSpine® (CELZ-201 ADAPT), Fast Track designation for CELZ-201-DDT, orphan drug designation for brittle Type 1 diabetes, and expansion of its iPSC and AI collaborations with Greenstone Biosciences.
Financially, the company reported an operating loss of about $6.1 million in 2025, research and development expense of about $2.3 million, minimal product revenue of $6,000, and cash and short‑term U.S. treasuries of about $7.2 million as of December 31, 2025. Management discloses a need for additional capital to fund ongoing trials and platform development.
Creative Medical Technology Holdings, Inc. is registering up to 2,790,340 shares of common stock for resale by existing investors, all issuable upon exercise of Inducement Warrants from an October 29, 2025 warrant exercise transaction. These are secondary sales by the selling stockholders, so the company will not receive any proceeds from the resale of the shares, although it has already received cash from the prior exercise of existing warrants and may receive additional funds if the new warrants are exercised for cash.
The Inducement Warrants currently have a $2.86 exercise price, were issued as part of an inducement for holders to exercise earlier warrants at $3.75 per share, and become exercisable for five years only after stockholder approval of the underlying share issuance. If all warrants are exercised, common stock outstanding would increase from 3,494,668 to 6,285,008 shares. Large holders such as Armistice Capital and Hudson Bay are subject to 4.99% or 9.99% beneficial ownership limits, and the company warns that significant resales could pressure the share price.
Creative Medical Technology Holdings, Inc. is registering 2,790,340 shares of common stock for resale by existing investors, issuable upon exercise of inducement warrants issued in an October 29, 2025 warrant exercise transaction. These are secondary sales, so the company will not sell any shares in this offering and will not receive proceeds from any resale, though it will receive cash if the warrants are exercised and plans to use those funds for working capital and general corporate purposes. The prospectus allows selling stockholders to dispose of shares in various ways over time, which could put pressure on the stock price if large blocks are sold. After full warrant exercise, common shares outstanding would be 6,045,440, based on 3,255,100 shares outstanding before the offering.